Immunovant (IMVT) to Release Earnings on Tuesday

Key Points

• Immunovant (NASDAQ: IMVT) is set to release its Q1 2026 earnings on August 5, with analysts anticipating a loss of ($0.69) per share.
• The company beat analysts' estimates in its last earnings report, posting ($0.64) EPS compared to an estimate of ($0.72) and generating $0.16 million in revenue.
• Insiders have sold a total of 7,869 shares in the past 90 days, reducing their ownership in the company, while institutional investors now hold approximately 47.08% of Immunovant's stock.

Immunovant (NASDAQ:IMVT - Get Free Report) is projected to announce its Q1 2026 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter.

Immunovant (NASDAQ:IMVT - Get Free Report) last issued its quarterly earnings results on Thursday, May 29th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.08. The company had revenue of $0.16 million during the quarter. During the same period in the previous year, the business posted ($0.52) earnings per share. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Stock Down 2.5%

Immunovant stock traded down $0.40 during mid-day trading on Friday, reaching $15.68. The company had a trading volume of 1,141,451 shares, compared to its average volume of 1,492,355. Immunovant has a 52 week low of $12.72 and a 52 week high of $34.47. The company has a 50 day moving average of $16.38 and a 200-day moving average of $17.52. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -5.73 and a beta of 0.63.

Insider Activity

In other Immunovant news, CTO Jay S. Stout sold 2,805 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total value of $50,910.75. Following the completion of the sale, the chief technology officer owned 204,919 shares in the company, valued at approximately $3,719,279.85. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael Geffner sold 2,385 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $43,287.75. Following the completion of the sale, the insider owned 221,825 shares of the company's stock, valued at $4,026,123.75. The trade was a 1.06% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,869 shares of company stock valued at $140,384 in the last 90 days. Corporate insiders own 1.80% of the company's stock.

Institutional Investors Weigh In On Immunovant

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its position in shares of Immunovant by 48.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company's stock worth $17,222,000 after buying an additional 329,354 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Immunovant by 8.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company's stock worth $708,000 after acquiring an additional 3,348 shares during the last quarter. Finally, Strs Ohio bought a new position in Immunovant during the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 47.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IMVT shares. UBS Group increased their price target on shares of Immunovant from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday. The Goldman Sachs Group raised shares of Immunovant to a "hold" rating and set a $18.00 price objective for the company in a report on Thursday, July 10th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $36.40.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.